These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 24693530)

  • 21. [Clinical value of prostate specific antigen screening in early detection of prostate cancer].
    Hua LX; Qiao D; Song NH; Feng NH; Yang J; Zhang JX; Chen JG; Zhang W; Sui YG; Wu HF
    Zhonghua Zhong Liu Za Zhi; 2009 Sep; 31(9):705-9. PubMed ID: 20021870
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Screening for prostate cancer at low PSA range: the impact of digital rectal examination on tumor incidence and tumor characteristics.
    Gosselaar C; Roobol MJ; Roemeling S; van der Kwast TH; Schröder FH
    Prostate; 2007 Feb; 67(2):154-61. PubMed ID: 17044079
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Association Between Lead Time and Prostate Cancer Grade: Evidence of Grade Progression from Long-term Follow-up of Large Population-based Cohorts Not Subject to Prostate-specific Antigen Screening.
    Assel M; Dahlin A; Ulmert D; Bergh A; Stattin P; Lilja H; Vickers AJ
    Eur Urol; 2018 Jun; 73(6):961-967. PubMed ID: 29066048
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Strategy for Prostate Cancer Patients with Low Prostate Specific Antigen Level (2.5 to 4.0 ng/mL).
    Chung JH; Yu J; Song W; Kang M; Sung HH; Jeon HG; Jeong BC; Seo SI; Lee HM; Jeon SS
    J Korean Med Sci; 2020 Oct; 35(41):e342. PubMed ID: 33107227
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ten year trend in prostate cancer screening with high prostate-specific antigen exposure rate in Japan.
    Okihara K; Kitamura K; Okada K; Mikami K; Ukimura O; Miki T
    Int J Urol; 2008 Feb; 15(2):156-60; discussion 161. PubMed ID: 18269453
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Age-Adjusted PSA Levels in Prostate Cancer Prediction: Updated Results of the Tyrol Prostate Cancer Early Detection Program.
    Heidegger I; Fritz J; Klocker H; Pichler R; Bektic J; Horninger W
    PLoS One; 2015; 10(7):e0134134. PubMed ID: 26218594
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Optimizing prostate cancer screening; prospective randomized controlled study of the role of PSA and PCA3 testing in a sequential manner in an opportunistic screening program.
    Rubio-Briones J; Casanova J; Dumont R; Rubio L; Fernandez-Serra A; Casanova-Salas I; Domínguez-Escrig J; Ramírez-Backhaus M; Collado A; Gómez-Ferrer A; Iborra I; Monrós JL; Ricós JV; Solsona E; Salas D; Martínez F; Lopez-Guerrero JA
    Actas Urol Esp; 2014 May; 38(4):217-23. PubMed ID: 24169211
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Population-based analysis of prostate-specific antigen (PSA) screening in younger men (<55 years) in Australia.
    Ranasinghe WK; Kim SP; Lawrentschuk N; Sengupta S; Hounsome L; Barber J; Jones R; Davis P; Bolton D; Persad R
    BJU Int; 2014 Jan; 113(1):77-83. PubMed ID: 24053128
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Detection rates and biologic significance of prostate cancer with PSA less than 4.0 ng/mL: observation and clinical implications from Tyrol screening project.
    Pelzer AE; Tewari A; Bektic J; Berger AP; Frauscher F; Bartsch G; Horninger W
    Urology; 2005 Nov; 66(5):1029-33. PubMed ID: 16286118
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The detection of significant prostate cancer is correlated with the Prostate Imaging Reporting and Data System (PI-RADS) in MRI/transrectal ultrasound fusion biopsy.
    Cash H; Maxeiner A; Stephan C; Fischer T; Durmus T; Holzmann J; Asbach P; Haas M; Hinz S; Neymeyer J; Miller K; Günzel K; Kempkensteffen C
    World J Urol; 2016 Apr; 34(4):525-32. PubMed ID: 26293117
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of dutasteride on prostate biopsy rates and the diagnosis of prostate cancer in men with lower urinary tract symptoms and enlarged prostates in the Combination of Avodart and Tamsulosin trial.
    Roehrborn CG; Andriole GL; Wilson TH; Castro R; Rittmaster RS
    Eur Urol; 2011 Feb; 59(2):244-9. PubMed ID: 21093145
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Disease-specific survival of men with prostate cancer detected during the screening interval: results of the European randomized study of screening for prostate cancer-Rotterdam after 11 years of follow-up.
    Zhu X; van Leeuwen PJ; Bul M; Otto SJ; de Koning HJ; Bangma CH; Schröder FH; Roobol MJ
    Eur Urol; 2011 Aug; 60(2):330-6. PubMed ID: 21601352
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [State of health of populations residing in geothermal areas of Tuscany].
    Minichilli F; Nuvolone D; Bustaffa E; Cipriani F; Vigotti MA; Bianchi F
    Epidemiol Prev; 2012; 36(5 Suppl 1):1-104. PubMed ID: 23139155
    [TBL] [Abstract][Full Text] [Related]  

  • 34. MRI ultrasound fusion biopsy in prostate cancer detection: Are randomized clinical trials reproducible in everyday clinical practice?
    Cattarino S; Forte V; Salciccia S; Drudi FM; Cantisani V; Sciarra A; Fasulo A; Ciccariello M
    Urologia; 2019 Feb; 86(1):9-16. PubMed ID: 30890102
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Racial differences in prediction of time to prostate cancer diagnosis in a prospective screening cohort of high-risk men: effect of TMPRSS2 Met160Val.
    Giri VN; Ruth K; Hughes L; Uzzo RG; Chen DY; Boorjian SA; Viterbo R; Rebbeck TR
    BJU Int; 2011 Feb; 107(3):466-70. PubMed ID: 20735386
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Association between literacy, compliance with prostate cancer screening, and cancer aggressiveness: results from a Brazilian screening study.
    Tobias-Machado M; Carvalhal GF; Freitas CH; Reis RB; Reis LO; Nogueira L; Machado RD; Magnabosco W; Vieira RA; Mauad EC; Carvalho AL; Faria EF;
    Int Braz J Urol; 2013; 39(3):328-34. PubMed ID: 23849582
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical efficacy of transrectal ultrasound-guided prostate biopsy in men younger than 50 years old with an elevated prostate-specific antigen concentration (>4.0 ng/mL).
    Lu CH; Lin TP; Shen SH; Huang YH; Chung HJ; Kuo JY; Huang WJS; Wu HHH; Chang YH; Lin ATL; Chen KK
    J Chin Med Assoc; 2017 Jul; 80(7):413-418. PubMed ID: 28529023
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prostate cancer screening using a combination of risk-prediction, MRI, and targeted prostate biopsies (STHLM3-MRI): a prospective, population-based, randomised, open-label, non-inferiority trial.
    Nordström T; Discacciati A; Bergman M; Clements M; Aly M; Annerstedt M; Glaessgen A; Carlsson S; Jäderling F; Eklund M; Grönberg H;
    Lancet Oncol; 2021 Sep; 22(9):1240-1249. PubMed ID: 34391509
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Are there regional tendencies toward controversial screening practices? A study of prostate and breast cancer screening in a Medicare population.
    Raffin E; Onega T; Bynum J; Austin A; Carmichael D; Bronner K; Goodney P; Hyams ES
    Cancer Epidemiol; 2017 Oct; 50(Pt A):68-75. PubMed ID: 28822325
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.